Enzon Announces Promotions to Executive Management Team
Mr. Davit has served as Enzon's senior vice president of human resources since January 2004 and vice president of human resources from March 2002 to January 2004. For more than 20 years, Mr. Davit has directed numerous human resource functions within various corporate settings, both as a member of executive management and in a consulting capacity. Prior to joining Enzon, Mr. Davit ran a human resources consulting practice. Previously, he spent over 12 years with Rhone-Poulenc Rorer, where he served as Vice President of Human Resources for RPR Gencell, Rhone-Poulenc Rorer's start-up biotechnology division, as well as vice president of human resources for the North American Pharmaceuticals division. Mr. Davit received his B.S. in psychology and sociology, M.S. in environmental science, and MBA in management science from Drexel University.
Mr. del Campo has over 30 years of diverse experience in the pharmaceutical industry, including serving as Enzon's senior vice president of technical operations since October 2002. Prior to joining Enzon, Mr. del Campo was the head of the North American operations of Elan Corporation, plc (NYSE: ELN). As part of Elan's acquisition of The Liposome Company, Mr. del Campo directed the start-up, scale-up, and ongoing operation of a sterile injectable manufacturing facility in Indianapolis. Mr. del Campo also spent over 17 years in various senior operations management positions at Bristol-Myers Squibb where he directed the growth of new laboratories, computerized manufacturing systems, and domestic operations effectiveness. Mr. del Campo received his B.S. in chemical engineering from the Newark College of Engineering and an MBA in pharmaceutical marketing from Fairleigh Dickinson University.
Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat life-threatening diseases. The Company has developed or acquired a number of marketed products, including PEG-INTRON(R), marketed by Schering-Plough, and ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R), marketed in North America by Enzon's specialized sales force. Enzon's science-driven strategy includes an extensive drug development program that leverages the Company's macromolecular engineering technology platforms, including PEG modification and single-chain antibody (SCA(R)) technologies. Internal research and development efforts are complemented by strategic transactions that provide access to additional marketed products and promising clinical compounds. Enzon has several drug candidates in various stages of development, independently and with partners. Further information about Enzon can be found on the Company's web site at www.enzon.com.
All information in this press release is as of April 15, 2005 and the Company undertakes no duty to update this information.
Contact Enzon Pharmaceuticals, Inc. Susan Mesco, 908-541-8678 Director, Investor Relations
Posted: April 2005